AVECTAS
Developer of a cell engineering platform intended to enable the ex vivo manufacture of gene-modified cell therapy products. The company's technology permeabilizes the target cell membrane and allows e...
Valuation
$71.5M
Market implied
Share Price
N/A
Total Raised
$82.7M
Last Round
N/A